|
Jun 24
|
Pipeline Moves: Approval prospects for BioTissue’s diabetic foot ulcer drug up after Phase III completion
|
|
May 13
|
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 13
|
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
|
May 1
|
Spruce Biosciences to Participate in May Investor Conferences
|
|
Apr 30
|
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
|
|
Apr 22
|
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
|
|
Mar 27
|
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
|
|
Mar 23
|
Revenue Downgrade: Here's What Analysts Forecast For Spruce Biosciences, Inc. (NASDAQ:SPRB)
|
|
Mar 21
|
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
|
|
Mar 16
|
Spruce Biosciences, Inc. (NASDAQ:SPRB) Just Reported Earnings, And Analysts Cut Their Target Price
|
|
Mar 13
|
Spruce Biosciences Inc (SPRB) Reports Full Year 2023 Financial Results Amid Clinical Trial Setbacks
|
|
Mar 13
|
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
|
|
Mar 13
|
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
|